|
Pronunciation |
|
(SOW
dee um hye al yoor ON
ate) |
|
|
U.S. Brand
Names |
|
AMO Vitrax®; Amvisc®;
Amvisc® Plus; Healon®; Healon®
GV |
|
|
Generic
Available |
|
No |
|
|
Synonyms |
|
Hyaluronic Acid |
|
|
Pharmacological Index |
|
Ophthalmic Agent, Viscoelastic |
|
|
Use |
|
Surgical aid in cataract extraction, intraocular implantation, corneal
transplant, glaucoma filtration, and retinal attachment
surgery |
|
|
Pregnancy Risk
Factor |
|
C |
|
|
Contraindications |
|
Hypersensitivity to hyaluronate |
|
|
Warnings/Precautions |
|
Do not overfill the anterior chamber; carefully monitor intraocular pressure;
risk of hypersensitivity exists |
|
|
Adverse
Reactions |
|
1% to 10%: Ocular: Postoperative inflammatory reactions (iritis, hypopyon),
corneal edema, corneal decompensation, transient postoperative increase in
IOP |
|
|
Stability |
|
Store in refrigerator (2°C to
8°C); do not freeze |
|
|
Mechanism of
Action |
|
Functions as a tissue lubricant and is thought to play an important role in
modulating the interactions between adjacent tissues. Sodium hyaluronate is a
polysaccharide which is distributed widely in the extracellular matrix of
connective tissue in man. (Vitreous and aqueous humor of the eye, synovial
fluid, skin, and umbilical cord.) Sodium hyaluronate forms a viscoelastic
solution in water (at physiological pH and ionic strength) which makes it
suitable for aqueous and vitreous humor in ophthalmic
surgery. |
|
|
Pharmacodynamics/Kinetics |
|
Absorption: Following intravitreous injection, diffusion occurs slowly
Elimination: By way of the Canal of Schlemm |
|
|
Usual Dosage |
|
Depends upon procedure (slowly introduce a sufficient quantity into
eye) |
|
|
Administration |
|
The drug may become cloudy or form a slight precipitate after administration;
clinical significance unknown, but cloudy or precipitated material should be
removed by irrigation or aspiration |
|
|
Monitoring
Parameters |
|
Intraocular pressure |
|
|
Dental Health: Local
Anesthetic/Vasoconstrictor
Precautions |
|
No information available to require special precautions |
|
|
Dental Health:
Effects on Dental Treatment |
|
No effects or complications reported |
|
|
Dosage Forms |
|
Injection, intraocular:
Healon®: 10 mg/mL (0.4 mL, 0.55 mL, 0.85 mL, 2 mL)
Amvisc®: 12 mg/mL (0.5 mL, 0.8 mL)
Healon® GV: 14 mg/mL (0.55 mL, 0.85 mL)
Amvisc® Plus: 16 mg/mL (0.5 mL, 8 mL)
AMO Vitrax®: 30 mg/mL (0.65 mL)
Injection (Hyalgan®): 10 mg/mL (2 mL)
|
|
Copyright © 1978-2000 Lexi-Comp Inc. All Rights Reserved
|